Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Red de investigación Renal

IP: Daniel Serón Micas
Collaborators: Joan López Hellin, Red de investigación Renal, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 92250
Reference: RD12/0021/0013
Duration: 01/01/2013 - 31/12/2016

Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome

IP: Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome
Collaborators: Joan López Hellin, Concepció Jacobs Cachá, Andrea Caballero Garralda
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 266200
Reference: SAF2011-29506
Duration: 01/01/2012 - 31/12/2014

Ministerio de Ciencia

Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)

IP: Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO/01/08
Duration: 01/02/2009 - 31/01/2011

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Joan López Hellin, Ramón Vilalta Casas, Alvaro Domingo Madrid Aris, Francesc Moreso Mateos, Enric Trilla Herrera, Daniel Serón Micas, Luis Enrique Lara Moctezuma, Concepció Jacobs Cachá, Carles Xavier Raventós Busquets
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2009 SGR 75
Duration: 01/01/2010 - 30/04/2014

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Gloria Fatou Royo Gomes

Gloria Fatou Royo Gomes

Main researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Fco. Javier Muñoz Gall

Fco. Javier Muñoz Gall

Main researcher
Pneumology
Read more
Lis Vidal Valdivia

Lis Vidal Valdivia

Donation and transplantation of organs, tissues and cells
Read more
Gabriel Sampol Rubio

Gabriel Sampol Rubio

Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.